A conflict-of-interest controversy has emerged within the Human Cell Atlas (HCA), a major international research effort to map every cell type in the human body. As the consortium celebrates its 10th anniversary, questions have been raised about a leader's undisclosed financial relationship with 10x Genomics, a key supplier of single-cell RNA sequencing technology used widely by HCA researchers.
The leader's ties to the California-based company, which markets a leading platform for analyzing individual cells, have prompted criticism from some scientists who argue the arrangement could influence research priorities or data access. The HCA has long prided itself on open science and collaboration, making the undisclosed link particularly sensitive. 10x Genomics declined to comment on the specific relationship.
According to STAT News, which broke the story, the leader has served as a paid scientific advisor to 10x Genomics while helping steer the HCA's strategic direction. The financial terms were not disclosed. Critics say such arrangements risk prioritizing a single vendor's technology in a project meant to be technology-agnostic, potentially biasing the atlas toward that platform's capabilities.
The episode underscores broader tensions in biomedical research, where academic leaders often hold equity or advisory roles in companies that supply essential tools. Some observers argue complete separation is unrealistic, while others call for stricter disclosure rules. The HCA said it is reviewing its conflict-of-interest policies in light of the report.